PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Dexamethasone - Retinal Vein Occlusion
PAD Profile : Dexamethasone - Retinal Vein Occlusion Important
Keywords :
RVO, CRVO, BRVO, macular oedema, branch retinal vein occlusion
Brand Names Include :
Ozurdex
Important Information :
Ophthalmology specialists only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends intravitreal dexamethasone (Ozurdex) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to branch or central retinal vein occlusion in line with NICE TA 229 (July 2011) and the NICE FAQ document relating to local formularies (link to document below). Intravitreal dexamethasone will be considered RED on the traffic light system
Associated BNF Codes
11. Eye
11.04.01. Corticosteroids